Foundayo, Eli Lilly's once-daily oral GLP-1 orforglipron, ended its first full month on the U.S. market with 1,390 prescriptions in its first full retail week per IQVIA data circulating among analysts — a slower opening than Lilly's recent injectable launches. [1] The April 1 FDA approval was the fastest review of a new molecular entity since 2002 and cleared the drug for adults with obesity or overweight with a related condition; the ATTAIN-1 readout the label rests on showed a 12.4% body-weight reduction at the highest dose over 72 weeks against a 2.2-pound placebo arm. [2]

The competitive wall around Foundayo is now two-sided. Novo Nordisk's oral semaglutide for obesity, Wegovy in pill form, was approved by the FDA in December 2025 and reached the market first; Lilly's pitch has been the convenience edge — orforglipron requires no fasting or water rules, and the molecule is small-molecule rather than peptide. [3] The second wall is pricing. The White House's TrumpRx framework continues to push direct-to-consumer obesity-drug pricing as a political priority; Lilly and Novo have both been forced into list-price concessions that compress the margin pads the injectables carried for three years.

The Idaho dairy H5N1 register and the measles 1,800-case wall are the noisier health stories on Monday. Foundayo is the quieter one with the longer demographic shadow: an obesity drug at a price the working middle reaches changes the demand curve for everything from bariatric surgery to airline seat-pitch.

-- NORA WHITFIELD, Chicago